公开(公告)号：US11839643B2

公开(公告)日：2023-12-12

申请号：US17327116

申请日：2021-05-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens Fritsche ,  Toni Weinschenk ,  Steffen Walter ,  Peter Lewandrowski ,  Harpreet Singh

IPC: A61P35/00 ,  C07K7/06 ,  A61K38/17 ,  A61K39/00 ,  G01N33/50

CPC classification number: A61K38/1709 ,  A61K39/0011 ,  A61P35/00 ,  C07K7/06 ,  G01N33/505 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2319/00

Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

公开(公告)号：US11298404B2

公开(公告)日：2022-04-12

申请号：US17492219

申请日：2021-10-01

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens Fritsche ,  Toni Weinschenk ,  Steffen Walter ,  Peter Lewandrowski ,  Harpreet Singh

IPC: A61P35/00 ,  C07K7/06 ,  A61K38/17 ,  A61K39/00 ,  G01N33/50

Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

公开(公告)号：US10357540B2

公开(公告)日：2019-07-23

申请号：US15639506

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Jens Fritsche ,  Toni Weinschenk ,  Steffen Walter ,  Peter Lewandrowski ,  Harpreet Singh

IPC: A61K38/04 ,  C07K7/06 ,  A61K38/17 ,  A61K39/00 ,  G01N33/50 ,  A61P35/00

Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.

公开(公告)号：US09717774B2

公开(公告)日：2017-08-01

申请号：US14615539

申请日：2015-02-06

Applicant: immatics biotechnologies GmbH

Inventor： Jens Fritsche ,  Toni Weinschenk ,  Steffen Walter ,  Peter Lewandrowski ,  Harpreet Singh

IPC: C07K7/06 ,  A61K38/17 ,  A61K39/00 ,  G01N33/50

CPC classification number: A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61P35/00 ,  C07K7/06 ,  C07K2319/00 ,  G01N33/505

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.